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Background: Conventional rTMS protocols for major depression commonly employ stimulation sessions
lasting >30 min. However, recent studies have sought to improve costs, capacities, and outcomes by
employing briefer protocols such as theta burst stimulation (iTBS).
Objective: To compare safety, effectiveness, and outcome predictors for DMPFC-rTMS with 10 Hz (30 min)
versus iTBS (6 min) protocols, in a large, naturalistic, retrospective case series.
Methods: A chart review identiﬁed 185 patients with a medication-resistant major depressive episode
who underwent 20-30 sessions of DMPFC-rTMS (10 Hz, n ¼ 98; iTBS, n ¼ 87) at a single Canadian clinic
from 2011 to 2014.
Results: Clinical characteristics of 10 Hz and iTBS patients did not differ prior to treatment, aside from
signiﬁcantly higher age in iTBS patients. A total 7912 runs of DMPFC-rTMS (10 Hz, 4274; iTBS, 3638) were
administered, without any seizures or other serious adverse events, and no signiﬁcant differences in
rates of premature discontinuation between groups. Dichotomous outcomes did not differ signiﬁcantly
between groups (Response/remission rates: Beck Depression Inventory-II: 10 Hz, 40.6%/29.2%; iTBS,
43.0%/31.0%. 17-item Hamilton Rating Scale for Depression: 10 Hz, 50.6%/38.5%; iTBS, 48.5%/27.9%). On
continuous outcomes, there was no signiﬁcant difference between groups in pre-treatment or post-
treatment scores, or percent improvement on either measure. Mixed-effects modeling revealed no sig-
niﬁcant group-by-time interaction on either measure.
Conclusions: Both 10 Hz and iTBS DMPFC-rTMS appear safe and tolerable at 120% resting motor threshold.
The effectiveness of 6 min iTBS and 30 min 10 Hz protocols appears comparable. Randomized trials
comparing 10 Hz to iTBS may be warranted.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).tic stimulation; MDD, major
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Repetitive transcranial magnetic stimulation (rTMS) is an
emerging treatment for medication-resistant major depressive
disorder (MDD), which affects approximately 2% of the population
[1]. The most recent studies of rTMS in MDD have achieved fairly
consistent response rates of 50e55% and remission rates of 30e35%
in naturalistic case series and open-label trials [2e4]. However,
although the ﬁrst human studies of rTMS in MDD took place nearly
25 years ago [5,6], the optimal parameters of stimulation are still
under investigation.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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used target for rTMS in MDD is the dorsolateral prefrontal cortex
(DLPFC). However, convergent evidence from lesion, stimulation,
neuroimaging, and connectivity studies also implicates a variety of
other prefrontal regions in MDD [7,8]. Of these, the DMPFC has
received the most attention to date. Recent case reports in MDD [9],
case series in MDD and bipolar disorder [10,11], and studies in post-
traumatic stress disorder [12] and eating disorders [13] have pro-
vided initial proof-of-concept evidence that DMPFC-rTMS may be
safe, tolerable, and effective in MDD and other mood and anxiety
disorders. However, as of this writing, it remains unclear whether
DMPFC-rTMS matches or exceeds the effectiveness of conventional
DLPFC stimulation overall, or indeed whether different sub-
populations of MDD patients might respond preferentially to
DMPFC- versus DLPFC-rTMS.
Another key parameter for optimization is the stimulation pro-
tocol itself. The most widely used protocol [14,15] applies 3000
pulses of 10 Hz stimulation to the left DLPFC over 37.5 min. How-
ever, lengthy protocols limit the number of patients who can be
treated per day per device, which in turn obliges a high cost-per-
session ($250e350 in many areas). A protocol with the same
effectiveness but shorter duration (5e10 min) could permit up to
ﬁve-fold increases in treatment capacity, which in turn would
permit lower treatment charges. Such improvements would greatly
facilitate wider affordability and adoption of rTMS as a mainstream
treatment for MDD, as has been seenwith other outpatient medical
procedures (such as laser vision correction) where technical im-
provements allowed higher case volumes and lower per-procedure
charges.
A promising form of patterned rTMS is theta-burst stimulation
(TBS), which applies 50 Hz triplet bursts ﬁve times per second [16].
Intermittent theta burst stimulation (iTBS), on a 2 s on/8 s off cycle,
delivers 600 pulses in just over 3 min. This pattern has been found
to have an excitatory effect whose potency matches or exceeds
much longer sessions of conventional rTMS [17]. If brief iTBS ses-
sions could be shown to have equivalent antidepressant effective-
ness to longer 10 Hz sessions, the translational implications for
rTMS capacity and affordability would be tremendous.
To date, at least 2 case series have used some form of TBS in
MDD, and each has demonstrated that TBS is safe, tolerable, and at
least comparably effective to conventional stimulation [18,19].
More recently, 2 randomized controlled trials have demonstrated
superior antidepressant efﬁcacy of TBS over sham rTMS [20,21].
However, as of this writing, there has been no explicit comparison
of the efﬁcacy of iTBS versus conventional 10 Hz stimulation in
MDD.
The deﬁnitive demonstration of non-inferiority for iTBS over
10 Hz rTMS will require a substantially larger patient sample and a
randomized controlled design. However, in the interim, evidence
from large-N, open-label case series may help to inform the design
of future studies. As an example, several large open-label series
have helped to establish the optimal course length for DLPFC-rTMS
in the average range 26e28 sessions [2,22].
We have previously reported outcomes, and neuroimaging
correlates of outcome, for two small case series of patients under-
going 10 Hz DMPFC-rTMS for a major depressive episode [10,11].
Here, we report data from a chart review of a larger series of 185
patients who received 20e30 sessions of open-label, add-on rTMS
of the left and right DMPFC, delivered as either 10 Hz stimulation or
iTBS, for treatment of a major depressive episode, over a 3-year
period at a single high-volume clinic. Data from patients receiving
DLPFC-rTMS will be reviewed in a subsequent work, due to an
insufﬁcient number of DLPFC cases available for analysis at present.
We hypothesized a priori based on previous observations [17] 1)
that both 10 Hz and iTBS of the DMPFC would be safe, tolerable, andeffective; 2) that iTBS would not differ signiﬁcantly from 10 Hz
DMPFC-rTMS in terms of effectiveness on self-reported or clinician-
rated measures. In addition, based on previous observations [11],
we hypothesized 3) that outcomes for DMPFC-rTMS would show a
non-normal, bimodal distribution for both 10 Hz and iTBS; 4) that
pre-treatment anhedonia symptoms would predict response to
DMPFC-rTMS using either iTBS or 10 Hz stimulation.
Materials and methods
Chart review and patient population
This chart review encompassed data on stimulation parameters,
tolerability, safety, and effectiveness on self- and clinician-rated
symptom scales for every patient who received open-label, add-
on rTMS of the bilateral DMPFC at the University Health Network’s
MRI-Guided rTMS Clinic between April 2011 and February 2014 for
treatment of a major depressive episode, whether in the context or
unipolar or bipolar illness. Throughout this period, this clinic
accepted community referrals and offered treatment without
charge to every referred patient free of pre-speciﬁed clinical con-
traindications to rTMS (active substance use disorders; psychotic
disorders; neurological disorders; rTMS or MRI contraindications,
including implanted devices, foreign ferromagnetic metal bodies,
uncontrolled cardiac arrhythmias, unstable medical conditions, a
history of epileptic seizures, traumatic brain injury or other central
neurological abnormality, or pregnancy). The deﬁned period for
this retrospective case series ended with the onset of substantial
recruitment volumes to a subsequent prospective randomized
controlled trial, currently in progress.
Following referral, all patients completed the Mini International
Neuropsychiatric Interview (MINI) 6.0 screen, and then underwent
a full clinical psychiatric assessment (including multi-axial diag-
nosis) by a Canadian Royal College-certiﬁed psychiatrist (JD or PG)
using DSM-IV criteria. Responses to the MINI screen were used to
identify diagnostic categories for additional scrutiny during inter-
view. All patients had a history of resistance to at least two
adequate medication trials (including discontinuations due to
adverse effects), and at least one trial in the current episode, based
on clinical interview supplemented by medical and pharmacy re-
cords. To maximize the generalizability of the reported results to
real-world practice, no co-morbidities were used as exclusion
criteria in this chart review. Likewise, in order to better reﬂect
clinical practice, treatment was offered to all patients with illness
severe enough that they were willing to attend a course of at least
20 sessions of rTMS; thus, no a priori minimum threshold of
symptom severity was applied. As a standard clinical practice, all
patients were required to maintain a consistent regimen of medi-
cations for 4 weeks prior to treatment, and throughout the treat-
ment course, to help disambiguate the source of any symptomatic
improvement or decline. All patients provided informed consent for
rTMS prior to initiating treatment, following UHN guidelines for
clinical procedure consent. This chart review was approved by the
Research Ethics Board of the University Health Network.
DMPFC-rTMS procedures
The neuronavigation, motor threshold, and coil placement pro-
cedures for DMPFC-rTMS, as practiced here, have been previously
described in detail elsewhere [10,13]. rTMS was delivered using a
MagPro R30 device equipped with a Cool D-B80 Coil (MagVenture,
Farum, Denmark) and a Qooler high-performance cooling system,
under MRI guidance using the Visor 2.0 system (Advanced Neuro
Technologies, Enschede, Netherlands) in all cases. Stimulation tar-
geted the left then right DMPFC at 120% of the resting motor
N. Bakker et al. / Brain Stimulation 8 (2015) 208e215210threshold for extensor hallucis longus. All patients initially received
20 sessions of treatment; those who achieved response but not
remission criteria were offered an additional 10 sessions. rTMS was
administered one session per day, 5 days perweek, for a total of 4e6
weeks. Missed sessions were added to the end of the treatment
course to achieve the target number of sessions per course; no
patient missed more than 4 cumulative sessions per course.
Each session of 10 Hz stimulation applied 3000 pulses to the left
hemisphere then again to the right hemisphere (6000 pulses total),
with a duty cycle of 5 s on and 10 s off, for a total stimulation time
w30 min. Each session of iTBS applied 600 pulses per hemisphere
(1200 pulses total), for a total stimulation time w6 min. As these
treatments were provided in a clinical context rather than a
research trial, patients were not randomly allocated. Instead, since
both treatments were permissible under Health Canada regula-
tions, treatment selection followed an informed consent discussion
with the patient, incorporating factors such as the extent of the
evidence base for safety and efﬁcacy, tolerability, and wait time to
begin treatment (wait times for iTBS were shorter due to the briefer
appointments required), as well as the availability of more con-
ventional alternatives to DMPFC-rTMS at public and private clinics
in the same downtown Toronto area. For consistency, a single
investigator (JD) conducted all such discussions.
Clinical assessments
A standard clinical practice was instituted for monitoring
progress in all patients undergoing rTMS for major depression.
Patients received baseline clinical assessments one week before
treatment, interim clinical assessments after each ﬁve sessions of
treatment, and follow-up clinical assessments 2, 4, 6, and 12 weeks
after treatment. Clinical assessments included the 17-item Hamil-
ton Rating Scale for Depression-17 (HamD17) [23] and the Beck
Depression Inventory-II (BDI-II) [24]. Response was deﬁned as
50% symptom reduction from pre-to post-treatment; remission
criteria were set at a post-treatment score 7 for HamD17, 12 for
BDI-II. Responder counts include remitters. The post-treatment
score was deﬁned as the ﬁrst available follow-up clinical assess-
ment in the window from 2 to 6 weeks post-treatment. Patients
with missing pre-treatment scores were excluded from calculating
response but not remission rates.
Data analysis
Data analysis methods are described in detail in the
Supplementary Material. Mixed-effects modeling, and kernel den-
sity estimation of the response distributions were performed in
Stata 13 (StataCorp, College Station, Texas, USA). False discovery
rate (FDR) correction, cumulative distribution function plotting, and
the KolmogoroveSmirnov and ShapiroeWilk testing of the
response distributions (in cases of non-normality) were calculated
in MATLAB (Mathworks, Natick, Massachusetts, USA). All data are
presented as mean  standard deviation.
Results
Demographic and clinical characteristics
A total of 185 patients underwent DMPFC-rTMS during the
deﬁned period (10 Hz, n ¼ 98; iTBS, n ¼ 87). The groups showed no
differences in proportion of males versus females, proportion of
unipolar versus bipolar illness, pre-treatment severity of illness on
HamD17 or BDI-II, length of current episode, number of previous
episodes, or number of previous medication trials (Table 1). How-
ever, iTBS patients were signiﬁcantly older than 10 Hz patients(10 Hz, 38.4  12.6; iTBS, 45.9  13.2; t183 ¼ 3.99, P ¼ 0.001, FDR-
corrected).
rTMS treatment parameters
Treatment parameters are summarized in Table 1. The total
number of stimulation runs performed in this series was 7912,
applied bilaterally during 3956 sessions, in 185 unique patients
(10 Hz: 4274 runs, 2137 sessions, 98 patients; iTBS: 3638 runs, 1819
sessions, 87 patients). Overall mean course length was 21.4  4.7
sessions, with no signiﬁcant difference between groups (10 Hz,
21.8  4.3; iTBS, 20.9  5.1; t183 ¼ 1.33, P ¼ 0.183). Expressed in
terms of maximum stimulator output, the mean stimulation in-
tensity (120% of resting motor threshold) did not differ signiﬁcantly
between groups for either left DMPFC (10 Hz, 64.6%  11.2%; iTBS,
65.1%  10.3%; t183 ¼ 0.35, P ¼ 0.724) or right DMPFC (10 Hz,
64.5%  11.0%; iTBS 65.0%  10.3%; t183 ¼ 0.29, P ¼ 0.770).
Safety and tolerability
No seizures or other serious adverse events occurred in any
patient during the period reviewed. Conﬁdence interval estimation
(via the adjusted Wald method) yields an estimated incidence rate
range for seizure or other serious adverse events at 0.0002 per
stimulation run (95% conﬁdence interval (CI), 0e0.0008), 0.0005
per session (95% CI, 0e0.0015), and 0.010 per patient (95% CI,
0e0.323) for 10 Hz DMPFC-rTMS. For iTBS, the corresponding es-
timates are 0.0003 per stimulation run (95% CI, 0e0.0009), 0.0005
per session (95% CI, 0e0.0018), and 0.011 per patient (95% CI,
0e0.362).
The all-causes premature discontinuation rate for 10 Hz stimu-
lationwas 6 of 98 patients (6.1%). 1 patient quit at 10 sessions due to
intolerable headaches, 2 patients quit at 18 sessions and 2 at 19
sessions due to lack of response, and 1 at 14 sessions due to
excessive commute time to the clinic. The all-causes premature
discontinuation rate for iTBS was 12 of 87 patients (13.8%). 2 pa-
tients quit at 9 and 16 sessions for intolerable headache, 1 at 11
sessions for intolerable vertigo, 1 at 19 sessions due to mood
improvement complicated by increasingly hostile thoughts toward
co-workers (but no manic symptoms), 2 at 11 and 19 sessions for
lack of response, 3 at 4, 10, and 11 sessions due to excessive
commute time, 2 at 16 and 18 sessions after achieving satisfactory
gains, and 1 for reasons unspeciﬁed. The proportion of patients
discontinuing due to adverse symptoms, lack of response, or un-
speciﬁed reasons did not differ signiﬁcantly between groups (10 Hz,
5/98; iTBS, 7/87; P ¼ 0.552, Fisher’s exact test). The proportion of
patients discontinuing due to any adverse symptom (headache/
vertigo/hostility) also did not differ signiﬁcantly between groups
(10 Hz, 1/98; iTBS, 4/87; P ¼ 0.189, Fisher’s exact test).
Treatment efﬁcacy e dichotomous outcomes
Among patients for whom HamD17 data was available, in the
10 Hz group, 42/83 (50.6%) achieved response and 37/96 (38.5%)
achieved remission. In the iTBS group, 32/66 (48.5%) achieved
response and 24/86 patients (27.9%) achieved remission. Among
patients with BDI-II data, in the 10 Hz group, 39/96 (40.6%) ach-
ieved response and 28/96 (29.2%) achieved remission. In the iTBS
group, 37/86 (43.0%) achieved response and 27/87 patients (31.0%)
achieved remission. There was no signiﬁcant difference in rates of
response or remission between groups on either measure (Table 2).
Combining available data from both groups, on the HamD17, 74/
149 (49.7%) achieved response, and 61/182 (33.5%) achieved
remission overall. On the BDI-II, 76/182 (41.8%) achieved response
Table 1
Demographic and clinical characteristics and treatment parameters for patients undergoing 10 Hz and iTBS DMPFC-rTMS.
Overall 10 Hz iTBS t P P (FDR)
Total sessions 3956 2137 1819 e e e
# patients 185 98 87 e e e
Female 127 70 57 e 0.429 0.770
Bipolar 29 17 12 e 0.549 0.770
Age 41.9  13.4 38.4  12.6 45.9  13.2 3.99 >0.001 0.001
Pre-treatment HamD17 21.7  6.2 22.1  6.9 21.1  5.1 1.03 0.303 0.770
Pre-treatment BDI-II 35.6  10.4 35.4  10.8 35.9  9.9 0.34 0.733 0.770
Length of current episode (months) 41.4  61.2 39.8  53.1 42.9  68.1 0.31 0.755 0.770
# previous episodes 4.6  8.8 4.1  8.3 4.9  9.2 0.40 0.689 0.770
# previous medication trials 6.2  3.9 5.9  3.9 6.5  3.9 0.89 0.375 0.770
# sessions/course 21.4  4.7 21.8  4.3 20.9  5.1 1.33 0.184 0.770
Stimulation intensity (Left) 64.8%  10.8% 64.6%  11.2% 65.1%  10.3% 0.35 0.724 0.770
Stimulation intensity (Right) 64.8%  10.6% 64.5%  11.0% 65.0%  10.3% 0.29 0.770 0.770
FDR, false discovery rate; iTBS, intermittent theta burst stimulation; HamD17, 17-item Hamilton Depression Rating Scale; BDI-II, Beck Depression Inventory-II.
Values indicate mean standard deviation. P-values are for two-sample t-statistics for continuous variable comparisons and for Fisher’s exact test for proportion comparisons.
Table 2
Dichotomous outcomes for patients undergoing 10 Hz and iTBS DMPFC-rTMS.
Overall 10 Hz iTBS P
HamD17
Response 74/149 (49.7%) 42/83 (50.6%) 32/66 (48.5%) 0.869
Remission 61/182 (33.5%) 37/96 (38.5%) 24/86 (27.9%) 0.157
BDI-II
Response 76/182 (41.8%) 39/96 (40.6%) 37/86 (43.0%) 0.765
Remission 55/183 (30.1%) 28/96 (29.2%) 27/87 (31.0%) 0.872
FDR, false discovery rate; iTBS, intermittent theta burst stimulation; HamD17, 17-
item Hamilton Depression Rating Scale; BDI-II, Beck Depression Inventory-II.
P-values are for Fisher’s exact text comparing the 10 Hz and iTBS outcomes.
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ations above reﬂect missing values.
Treatment efﬁcacy e continuous outcomes
On the HamD17, symptoms improved from 22.4  6.5 to
12.3  8.9 (decreasing 44.3%  35.5%) in the 10 Hz group and from
21.1 5.1 to 12.7  7.9 (decreasing 43.6%  35.6%) in the iTBS group
(Fig. 1A). The mixed-effects model revealed a signiﬁcant main effect
of time (z ¼ 5.90, P < 0.001) but not of group (z ¼ 0.01,
P ¼ 0.994). Notably, the group by time interaction was non-
signiﬁcant (z ¼ 0.72, P ¼ 0.473). There was also no signiﬁcant
difference in pre-treatment, post-treatment scores or percent
improvement between groups (Table 3).
Likewise, on the BDI-II, symptoms improved from 35.3  10.8 to
22.4  15.5 (decreasing 38.4%  36.6%) in the 10 Hz group and from
35.9  9.9 to 20.2  13.3 (decreasing 42.6%  32.2%) in the iTBS
group (Fig. 1B). Here again, the mixed-effects model revealed a
signiﬁcant main effect of time (z ¼ 9.02, P < 0.001) but not of
group (z ¼ 0.11, P ¼ 0.910). The group by time interaction was also
non-signiﬁcant (z ¼ 1.84, P ¼ 0.066) and trending in favor of iTBS
over 10 Hz stimulation. There was no signiﬁcant difference in pre-
treatment, post-treatment BDI-II scores or percent improvement
between groups (Table 3).
On further examination, the ShapiroeWilk test revealed a
signiﬁcantly non-normal distribution of outcomes in both the 10 Hz
group (HamD17: W ¼ 0.958, P ¼ 0.010; BDI: W ¼ 0.973, P ¼ 0.042)
and the iTBS group (HamD17:W¼ 0.969, P ¼ 0.093; BDI:W ¼ 0.957,
P ¼ 0.007); the HamD17 distribution in the iTBS group trended to-
ward non-normality without reaching signiﬁcance. On inspection
of the kernel density estimates for each group and each measure,
the distribution appeared trimodal in most cases, with a distinct
non-responder and responder subgroup as well as intermediate,
partial responder subgroup (Fig. 2).
In light of the non-normal distributions of outcomes, we also
performed a non-parametric (two-sample KolmogoroveSmirnov)
comparison of the cumulative distribution functions for the degree
of improvement across all subjects in each group. Once again, there
was no signiﬁcant difference between 10 Hz and iTBS outcomes on
either the HamD17 (D ¼ 0.07, P ¼ 0.991) or BDI-II (D ¼ 0.108,
P ¼ 0.646) (Fig. 3).
Finally, due to the non-normal distributions of outcomes, in
order to rule out the possibility of subtle differences in the effec-
tiveness of 10 Hz versus iTBS that might be apparent in responders
alone, we separated the responder and non-responder individuals,
then repeated the mixed-effects model analysis using only the
responder patients (Fig. 4). Once again, on the HamD17, theresponder subgroup showed a signiﬁcant main effect of time
(z ¼ 7.70, P < 0.001) but not of group (z ¼ 1.00, P ¼ 0.316), and
the group by time interaction was also non-signiﬁcant (z ¼ 0.11,
P ¼ 0.914). On the BDI-II, the responder subgroup showed a sig-
niﬁcant main effect of time (z ¼ 10.4, P < 0.001), and a signiﬁcant
main effect of group with the iTBS group showing slightly more
severe illness in general (z ¼ 2.05, P ¼ 0.041). Here the group by
time interaction showed a small but signiﬁcant effect in favor of
iTBS over 10 Hz stimulation (z ¼ 2.35, P ¼ 0.019).
Predictors of outcome
Demographic, clinical, and rTMS parameter predictors of
outcome are presented in Table 4. Neither the 10 Hz group, nor the
iTBS group, nor the combined set of both groups showed any sig-
niﬁcant correlation (post-FDR-correction) between percent
improvement on the HamD17 and any of the following variables:
age, sex, unipolar/bipolar illness, pre-treatment HamD17 or BDI
score, length of current episode, number of previous episodes,
number of previous medication trials, number of treatment ses-
sions, or stimulation intensity. We also examined each individual
item on the pre-treatment HamD17 and BDI-II scales for correlation
to improvement on the HamD17 post-treatment (Tables S1eS3,
Supplementary Material). Across all patients, only BDI-Pessimism
(P ¼ 0.047) and BDI-Indecisiveness (0.024) signiﬁcantly correlated
to HamD17 outcome following FDR-correction.
Discussion
To our knowledge, this case series of 185 patients is the largest
thus far reported for patients receiving DMPFC-rTMS for a major
depressive episode. Consistent with our ﬁrst hypothesis, both iTBS
and 10 Hz stimulation appear to be safe and well tolerated, with no
serious adverse events in >7900 stimulation runs, and no
Figure 1. Change in symptom severity over the course of treatment for patients receiving DMPFC-rTMS, using a 30-min 10 Hz (n ¼ 98, blue) or a 6 min iTBS (n ¼ 87, red) protocol, on
the HamD17 (A) and the BDI-II (B) symptom scales. Mixed-effects modeling revealed a signiﬁcant main effect of time (P < 0.001) but not of group (P ¼ 0.994), and no signiﬁcant
group by time interaction (0.473) on the HamD17. The same was true for the main effect of time (P < 0.001), group (P ¼ 0.910), and the group by time interaction (P ¼ 0.066) on the
BDI-II. HamD17, 17-item Hamilton rating scale for depression; BDI-II, Beck Depression Inventory-II. iTBS, intermittent theta burst stimulation.
N. Bakker et al. / Brain Stimulation 8 (2015) 208e215212signiﬁcant differences between groups in rates of discontinuation
due to adverse effects. The safety proﬁle of iTBS is particularly
notable given that it was administered at the same stimulation
intensity as 10 Hz rTMS: 120% of resting motor threshold for lower
extremity movements. Not only is the motor threshold for the
lower extremity approximately some 50% higher than for the upper
extremity, but the multipliers commonly used for iTBS are also
typically much lower: i.e., 80% of active (not resting) motor
threshold [16,17,25,26]. This much lower intensity was also used in
the most recent trials of TBS targeting DLPFC in major depression
[20,21]. However, the absence of seizures or other adverse events,
and equivalent tolerability across 3638 runs of stimulation in 87
individuals suggests that iTBS might be safely performed at the
same intensity as 10 Hz stimulation, at least for the DMPFC target.
Regarding effectiveness, in keeping with our second hypothesis,
iTBS matched or exceeded the effectiveness of 10 Hz stimulation onTable 3
Continuous outcomes for patients undergoing 10 Hz and iTBS DMPFC-rTMS.
10 Hz iTBS t P
All patients
Pre-treatment
HamD17 22.1  6.9 21.1  5.1 1.03 0.303
BDI-II 35.4  10.8 35.9  9.9 0.34 0.733
Post-treatment
HamD17 12.3  8.9 12.7  7.9 0.32 0.750
BDI-II 22.4  15.5 20.2  13.3 1.03 0.307
% improvement
HamD17 44.3%  35.5% 43.6%  35.6% 0.12 0.905
BDI-II 38.4%  36.6% 42.6%  32.2% 0.82 0.415
Responders only
Pre-treatment
HamD17 20.8  6.9 21.3  4.9 0.35 0.729
BDI-II 32.0  11.2 36.5  8.0 2.01 0.049
Post-treatment
HamD17 5.7  3.8 6.0  3.9 0.33 0.740
BDI-II 14.1  10.9 11.3  7.6 1.29 0.200
% improvement
HamD17 71.4%  18.2% 72.4%  16.2% 0.25 0.807
BDI-II 55.4%  29.3% 67.9%  22.3% 2.08 0.041
FDR, false discovery rate; iTBS, intermittent theta burst stimulation; HamD17, 17-
item Hamilton Depression Rating Scale; BDI-II, Beck Depression Inventory-II.
Values indicate mean  standard deviation.both clinician and self-rated measures, despite requiring 5-fold
fewer pulses and time to administer. The pace of improvement
over time was also equal (or signiﬁcantly better) for iTBS versus
10 Hz stimulation. Although patients were not prospectively ran-
domized in this naturalistic series, there were no signiﬁcant dif-
ferences in demographic or clinical characteristics between groups,
aside from higher age in the iTBS group. Thus, it is unlikely that the
equivalent effectiveness of iTBS in this series can be accounted for
solely in terms of less severe or less refractory illness in the iTBS
versus the 10 Hz group.
As hypothesized, the distribution of outcomes was signiﬁcantly
non-normal on 3 out of the 4 plots and trending to non-normality on
the fourth. Althoughourprevious studyof 10HzDMPFC-rTMS found
a bimodal outcome distribution [11], the present series identiﬁed a
more complex response distribution, appearing closer to trimodal
across all 4 combinations ofmeasures and interventions. In addition
to responder and non-responder subgroups, each of the kernel
density estimates revealed signs of an intermediate “partial
responder” group, with a peak around 50e60% improvement, more
apparent on self-report than clinician ratings (Fig. 2).
We have previously found that the response to 10 Hz DMPFC-
rTMS could be predicted by anhedonia-related symptoms: pessi-
mism, loss of pleasure, and loss of interest [11]. In this larger series,
only BDI-Pessimism and BDI-Indecisiveness showed a signiﬁcant
correlation to HamD17 outcome in the combined sample after
correction formultiple comparisons (Supplementary Tables S1eS3).
No single item, and no clinical or demographic feature, signiﬁcantly
predicted outcome in both groups independently. Thus, this larger
sample did not conﬁrm the utility of anhedonia symptoms, or any
other clinical features, for predicting treatment outcome across
10 Hz or iTBS DMPFC-rTMS independently.
The original rationale for pursuing rTMS of the DMPFC rather
than the conventional DLPFC was to achieve better outcomes by
targeting a region potentially more central to depression patho-
physiology [7,27e29]. However, the present case series yielded
overall response and remission rates of 49.7% and 33.5% (HamD17),
and 41.8% and 30.0% (BDI-II). These rates are not, in fact, superior to
rates reported in other open-label series using DLPFC-rTMS: 41.2%
and 35.3% in n ¼ 85 [4], 51.6% and 34.4% in n ¼ 93 [3], 41.0% and
30.5% in n ¼ 141 [22], and 58.0% and 37.1% in n ¼ 307 [2]. This may
indicate that DMPFC-rTMS offers no efﬁcacy advantages over
Figure 2. Kernel density estimates of the distributions of outcomes (expressed as percentage improvement from pre-treatment to ﬁrst post-treatment follow-up) in patients
receiving 10 Hz stimulation on HamD17 (A) and BDI-II (B) measures, and in patients receiving iTBS on HamD17 (C) and BDI-II (D) measures. HamD17, 17-item Hamilton rating scale
for depression; BDI-II, Beck Depression Inventory-II. iTBS, intermittent theta burst stimulation.
N. Bakker et al. / Brain Stimulation 8 (2015) 208e215 213DLPFC-rTMS. Alternatively, broad access to treatment in this series
may have allowed inclusion of patients withmore refractory illness.
It is also possible that DMPFC-rTMS and DLPFC-rTMS treat two
different but roughly equal-sized subpopulations of MDD patients.
Resolution of these issues must await a randomized trial comparing
the two techniques directly.
The present report carried several important limitations. First,
patients were not allocated randomly or prospectively, leaving open
the possibility that some systematic allocation bias may have made
the treatments appear more similar in efﬁcacy than they are in
reality. Second, the target of stimulationwas the DMPFC rather than
the standard DLPFC, leaving open the possibility that the ﬁndings
may not generalize to the much more widely used DLPFC target.
Likewise, because of the insufﬁcient number of patients receivingFigure 3. Empirical cumulative distribution function plots comparing the outcomes (express
patients receiving 10 Hz stimulation versus iTBS on HamD17 (A) and BDI-II (B) measures. K
either the HamD17 (P ¼ 0.991) or the BDI-II (P ¼ 0.646). HamD17, 17-item Hamilton rating
stimulation.DLPFC stimulation at the clinic during the reviewed period, the
present study does not allow for a comparison of outcomes for
DLPFC- versus DMPFC-rTMS, whether unilateral or bilateral. Finally,
the patient sample in this study was more broadly inclusive than in
most randomized controlled trials of rTMS. Although the broad
inclusion criteria were intended to make the ﬁndings more gener-
alizable to real-world practice, the resultant heterogeneity may
have obscured some potentially relevant predictors of outcome.
Thus, in a more clinically homogenous sample, several of the clin-
ical, demographic, and symptom items surveyed in this study could
prove to be more reliable outcomes predictors. In particular, the
lack of a structured assessment of medication resistance (e.g., the
Antidepressant Treatment History Form) in the available clinical
data may have obscured the role of medication resistance ined as percentage improvement from pre-treatment to ﬁrst post-treatment follow-up) in
olmogoroveSmirnov test revealed no signiﬁcant differences in these distributions on
scale for depression; BDI-II, Beck Depression Inventory-II. iTBS, intermittent theta burst
Figure 4. Change in symptom severity over the course of treatment for responder patients only (50% improvement), using a 30-min 10 Hz (n ¼ 98, blue) or a 6 min iTBS (n ¼ 87,
red) protocol, on the HamD17 (A) and the BDI-II (B) symptom scales. Mixed-effects modeling revealed a signiﬁcant main effect of time but not of group, and no signiﬁcant group by
time interaction, on the HamD17. On the BDI-II, there was a signiﬁcant effect of time (P < 0.001), and of group (P ¼ 0.041) with more severe illness in the iTBS group, and a signiﬁcant
group by time interaction favoring iTBS over 10 Hz rTMS (P ¼ 0.019). HamD17, 17-item Hamilton rating scale for depression; BDI-II, Beck Depression Inventory-II. iTBS, intermittent
theta burst stimulation.
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DLPFC-rTMS outcome predictors: age and number of previous
failed medication trials [30], episode duration [31], extraversion
[32], sleep disturbance [33], apathy symptomatology [34], and
HamD17 items for depressed mood and guilt [35]. A prospective
study with more rigidly deﬁned inclusion criteria, and more
structured assessment of medication resistance, could reveal
whether these predictors apply to DMPFC-rTMS as well.
Regarding future directions, the present ﬁndings are supportive
for proceeding to a randomized trial comparing 3 min iTBS to the
standard 37.5 min 10 Hz protocol [14,15] at the conventional left
DLPFC target. Even if iTBS proved merely non-inferior to conven-
tional stimulation, this would still allow up to a ﬁve-fold increase in
capacity and decrease in cost-per-session, on existing infrastruc-
ture. iTBS could potentially reduce the cost of rTMS to under $1000
for 20 sessions, while expanding the capacity of each clinic to >25
patients/device/day. Less expensive, higher-throughput protocols
would constitute amajor step forward towardwidespread adoption
of rTMS as a mainstream alternative/adjunct to medications and
psychotherapy in MDD patients.
Another important follow-up study would involve a randomized
comparison of DMPFC and DLPFC stimulation. Ideally, such a study
would characterize individual patients as comprehensively asTable 4
Demographic, clinical and treatment parameter predictors of outcome.
10 Hz iTBS All patients
r P r P r P
Age >0.001 0.998 0.223 0.072 0.091 0.272
Female 0.008 0.946 0.160 0.199 0.069 0.405
Bipolar 0.083 0.456 0.028 0.821 0.039 0.633
Pre-treatment HamD17 0.089 0.426 0.030 0.811 0.042 0.612
Pre-treatment BDI-II 0.275 0.012 0.038 0.763 0.176 0.032
Length of current episode 0.199 0.118 0.050 0.705 0.062 0.500
# previous episodes 0.210 0.233 0.154 0.314 0.082 0.474
# previous medication trials 0.082 0.483 0.044 0.752 0.038 0.670
# sessions 0.113 0.310 0.156 0.212 0.133 0.106
Stimulation intensity (left) 0.023 0.837 0.042 0.737 0.031 0.709
Stimulation intensity (right) 0.019 0.867 0.085 0.496 0.048 0.568
FDR, false discovery rate; iTBS, intermittent theta burst stimulation; HamD17, 17-
item Hamilton Depression Rating Scale; BDI-II, Beck Depression Inventory-II.possible prior to treatment, using clinical and behavioral measures
as well as biological markers such as neuroimaging, electrophysi-
ological, and genomic studies. These data would be essential for
addressing whether DLPFC- and DMPFC-rTMS treat similar or
distinct subpopulations of MDD patients. If the latter case, these
data could also prove useful in identifying predictive biomarkers to
guide the choice of stimulation target in individual patients pre-
senting for rTMS treatment.
Conclusions
The parameters of rTMS are still being optimized, nearly 20
years after the ﬁrst use of the technique. The present study suggests
that DMPFC-rTMS can be performed safely and tolerably at high
stimulation intensities, and that 3 min iTBS protocols may match
the efﬁcacy of much longer 10 Hz protocols. The overall effective-
ness of DMPFC-rTMS appears comparable to, but not markedly
superior to, standard DLPFC-rTMS. Randomized trials comparing
iTBS versus 10 Hz stimulation, and DMPFC- versus DLPFC-rTMS,
will provide a more rigorous test of which techniques can achieve
optimal outcomes, both in MDD in general, and in individual
patients.
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